GlassScriptPhysician profile
Dhruv Patel
NPI 1699740613
$402,013.41
in general payments reported to CMS, 2019-2025
65 companies · $7,323 in 2025
The $7,323 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138K · 2020: $72K · 2021: $103K · 2022: $51K · 2023: $25K · 2024: $6,439 · 2025: $7,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $10K · Food and Beverage: $4,841 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,886.25 |
| Consulting Fee | $10,380.00 |
| Food and Beverage | $4,841.24 |
| Education | $218.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84,077.64 | 2019-2025 | Uplizna |
| Abbvie INC. | $81,296.62 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $45,151.64 | 2019-2024 | Austedo Xr, Austedo |
| Genzyme Corporation | $39,425.93 | 2019-2023 | |
| Mdd US Operations, LLC | $25,004.37 | 2019-2023 | Apokyn |
| Mallinckrodt Hospital Products INC. | $22,457.75 | 2020-2025 | Acthar |
| Emd Serono, INC. | $18,771.02 | 2019-2025 | Mavenclad |
| Allergan, INC. | $18,761.03 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $16,273.30 | 2022-2023 | Trudhesa |
| Mallinckrodt Enterprises LLC | $14,092.91 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14,051.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,415.78 | 2022 | |
| Avanir Pharmaceuticals, INC. | $4,570.08 | 2019-2021 | |
| Eisai INC. | $3,081.23 | 2019-2024 | |
| Biogen, INC. | $1,514.28 | 2019-2023 | Tysabri, Vumerity |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhruv Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.